MeiraGTx (MGTX) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MeiraGTx (MGTX) has outperformed Prime Medicine (PRME) over the past year, gaining 7.0% versus a loss of 2.2%. Prime Medicine is the larger company by market cap ($791.6 million vs $779.9 million), about 1.0 times the size, while MeiraGTx is growing revenue faster (+144.6% vs +55.3%). MeiraGTx converts more of its revenue into profit, with a net margin of -140.3% versus -4342.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | PRME |
|---|---|---|
| Share price | $7.98 | $3.55 |
| Market cap | $779.89M | $791.62M |
| 1-day change | -1.97% | -7.55% |
| YTD return | +0.38% | +2.31% |
| 1-year return | +6.97% | -2.20% |
| 5-year return | -55.54% | — |
| P/E ratio (TTM) | 9.17 | — |
| EPS (TTM) | $0.87 | $-0.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $81.39M | $4.63M |
| Revenue growth (YoY) | +144.57% | +55.28% |
| Net income (latest FY) | $-114.20M | $-201.14M |
| Operating margin | -130.20% | -4498.06% |
| Net margin | -140.31% | -4342.44% |
| 52-week high | $15.35 | $5.91 |
| 52-week low | $6.62 | $2.67 |
| Distance from 52-week high | -48.01% | -39.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +247.74% | +108.17% |
| Average volume | 837.25K | 4.64M |
| Shares outstanding | 97.73M | 222.99M |
| Employees | 386 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MeiraGTx is more profitable, keeping -140.3 cents of every revenue dollar as net income versus -4342.4 cents for Prime Medicine.
- MeiraGTx grew revenue faster in its latest fiscal year (+144.57% vs +55.28%).
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 386 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
MGTX vs PRME FAQ
Which is bigger, MeiraGTx or Prime Medicine?
Prime Medicine (PRME) is larger, with a market capitalization of $791.62M compared with $779.89M for MeiraGTx (MGTX).
Which stock has performed better over the past year, MGTX or PRME?
MGTX returned +6.97% over the past 12 months, compared with -2.20% for PRME (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Prime Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.